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Abstract 
 
Kate Garner:  Assessment of Physical Health Outcomes in an Enhanced Primary Care Model:  
Weight and BMI Outcomes for Patients with Severe Mental Illness at WakeBrook Primary Care 
Clinic 
 
(Under the Direction of Sue Tolleson-Rinehart, PhD) 
 
Introduction: Approximately 9.6 million people in the United States are diagnosed with Severe 
Mental Illness (SMI), a term applying to any diagnosable mental, behavioral, or emotional 
disorder resulting in substantial functional impairment, but most often used to describe persons 
with diagnoses of schizophrenia spectrum disorders, bipolar disorder, and recurrent major 
depressive disorder with psychotic features.  The average life expectancy of individuals with 
SMI is approximately 8-25 years shorter than is the lifespan of those without SMI.  Lack of 
access by persons with SMI to quality preventive and primary care services has led to 
disproportionately high morbidity and mortality from chronic medical conditions such as 
hypertension, diabetes, obesity, and cardiovascular disease.  The WakeBrook Primary Care 
office, a primary care clinic embedded within a mental health facility, hopes to address these 
health disparities through their innovative Enhanced Primary Care Model, which has already 
improved access to and utilization of quality primary care.  This study of changes in weight and 
BMI over time assesses whether WakeBrook’s model has been successful to date at improving 
physical health outcomes. 
  
Methods: In this retrospective chart review, I identified patients already participating in a 
SAMHSA-funded grant project and enrolled in the Enhanced Primary Care Model at the 
WakeBrook Primary Care Office for at least 18 months and who were currently enrolled without 
lapses in care as of the study censoring date (January 28, 2019).  I determined participants’ 
length of enrollment in the model, extracted weight and BMI data at 6-month intervals until the 
study censoring date (the primary outcome indicators) from their electronic medical records, and 
descriptive statistics, paired t-tests, and logistic regression models. 
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Results: A majority of the 119 eligible WakeBrook patients were obese at the time of enrollment 
(59.7%), diagnosed with a schizophrenia spectrum disorder (50.4%), and prescribed at least 
one atypical antipsychotic (68.9%).  These patients were likely also to have hypertension 
(61.3%), diabetes (34.5%), and dyslipidemia (52.9%).  Mean weight and BMI significantly 
increased after 12 months of enrollment of +2.02 kg (95% CI 0.47 to 3.58) and +0.77 kg/m2 
(0.19 to 1.36), but BMI classification and distribution changed little over time.  Logistic 
regression modeling showed that longer enrollment in the program (>23 months) was 
apparently more associated with obseity at the end of the study period (OR 2.49, 95% CI 1.06 to 
5.87) than was shorter enrollment (18-22 months) after adjusting for age and diagnoses of 
hypertension, diabetes, and dyslipidemia. 
  
Discussion: The study suggests that weight gain and obesity, significant health concerns in 
patients with SMI, are not significantly improved by being assigned to a medical home.  This 
study did not collect number of visits to the practice or number of sessions with health education 
staff, and it cannot make inferences about the intervention beyond being assigned to a medical 
home.  This study emphasizes that carefully examining different components of care is essential 
to our understanding of obesity and weight gain in patients with SMI.  A more comprehensive 
study design, including carefully matched controls, is necessary to draw firm conclusions about 
whether structured, protocolized interventions successfully promote weight loss and 
maintenance.  Future research and policy recommendations should focus on the development 
of enhanced EMR infrastructure and better systems of measurement to allow for continuous 
data collection, robust analysis, and longitudinal follow-up.  In-depth interviews to assess patient 
perceptions of current weight loss programs would also be helpful.  This expanded research 
design has the potential to inform future programming decisions to improve care and health 
outcomes of patients diagnosed with SMI.  
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Introduction 
The term Severe Mental Illness (SMI) applies to a variety of diagnosable mental, 
behavioral, or emotional disorders that result in substantial functional impairment in 
accomplishing activities of daily living; the term SMI most commonly applies to those who have 
been diagnosed with schizophrenia spectrum disorders, bipolar disorder, and recurrent major 
depressive disorder with psychotic features.1–3  As of 2012, approximately 9.6 million adults in 
the United States, or 4-8% of all adults, are diagnosed with some form of SMI.1,4  In addition to 
mental health concerns, persons with SMI also have an average life expectancy 8-25 years 
shorter than that of the general population.1,3,5,6   Suicide and injury can only account for an 
estimated 40% of this excess mortality in patients diagnosed with SMI.6  Contrary to what may 
be expected, the leading cause of death among individuals with SMI who access the public 
health system is heart disease, and premature cardiovascular disease is primarily responsible 
for the shorter life expectancies associated with SMI.1,6–8  It is estimated that more than two-
thirds of all individuals with a mental illness have at least one chronic, non-communicable 
medical disease.9  The risk of diabetes, dyslipidemia, hypertension, and obesity for persons with 
SMI is two to three times higher than for the general public, and they are twice as likely to die 
prematurely from such conditions.2,6,10   
The relationship between mental and physical illness is complex and dynamic.  Risk 
factors for cardiovascular disease, diabetes, and other non-communicable diseases are 
especially prevalent among persons with SMI for several personal, environmental, and 
treatment-based reasons.9,11  For example, many pharmacologic treatments for severe mental 
illness, such as atypical antipsychotics, have notable cardiometabolic effects and contribute to 
sustained weight gain, hyperglycemia, and dyslipidemia.7,9  Up to 80% of people treated with 
antipsychotics end up with medication-induced weight gain.5  One study found that the average 
weight gain after 10 weeks of atypical antipsychotic pharmacologic therapy was 0.5 to 5.0 kg 
versus placebo, and 78.8% of patients receiving antipsychotic agents increased their baseline 
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weight by more than 7%.12  These high rates of metabolic syndrome and obesity in this 
population have also contributed to reduced quality of life and mobility, increased social 
marginalization, and increased risk for diabetes, hypertension, and coronary artery disease.5,8  
Symptoms from one mental or medical illness may worsen or contribute to the progression of 
another condition.3  It has also been hypothesized that mental illness itself may be an 
independent direct and indirect risk factor for cardiovascular disease and type 2 diabetes.1,8  
Many of the risk factors for cardiovascular disease and diabetes that are the most prevalent 
among individuals with SMI, such as smoking, obesity, physical inactivity, poor nutrition, and 
substance use, are modifiable, and they may be addressed in both behavioral health and 
medical settings.1,7   
 Nonetheless, it is unlikely that the disparities in health outcomes between the general 
population and individuals with SMI are solely due to higher prevalence of risk factors and 
chronic illness.  The burden of suffering due to chronic and preventable medical illnesses in 
patients with SMI is exacerbated by lower rates of preventive care and health care utilization.6,13  
For example, up to 70% of cases of type II diabetes in  people with SMI are undiagnosed versus 
only 25-30% of such cases in the population without mental illness.8  Because increased 
severity of psychiatric symptoms is associated with greater perceived barriers to care, those 
with schizophrenia and other SMI are much less likely to have visited a primary care provider in 
the past year compared to those without mental illness.14,15  Effective utilization and navigation 
of the fragmented health system is complicated by the fact that individuals with SMI may suffer 
from cognitive deficits and are less likely to have financial resources, stable living conditions, 
and strong social supports2,14,16  Even after controlling for demographics, income, and insurance 
status, individuals with psychotic and bipolar disorders are still less likely to have a primary care 
provider.1  This lack of a medical home has resulted in overreliance on expensive emergency 
care services, suboptimal care for both physical and mental health conditions, and increased 
mortality, morbidity, and functional impairment.1,9,14,17   
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Some studies have shown that access to consistent, quality primary care has a 
demonstrated survival benefit for patients with schizophrenia regardless of whether they have a 
comorbid medical diagnosis; coordinated primary care and behavioral health has been shown to 
contribute to better control of blood pressure, hemoglobin A1c, lipid levels, obesity, and other 
cardiovascular risk factors for these patients.13,18  Unfortunately, the quality of care that patients 
with SMI are able to access is often poor in comparison to the care of individuals without mental 
illness.  Signs, symptoms and risk factors for chronic disease may be missed or ignored by 
providers who struggle to manage the complex psychiatric and medical needs of patients with 
SMI.11  Even when these chronic medical conditions are recognized by health care providers, 
research suggests that patients with SMI still do not receive the standard of care recommended 
in published guidelines.9,17  Traditional care models are ill equipped to respond properly to this 
complex, often stigmatized patient population.19  Patients with SMI often have high no-show 
rates, often attributable to worsening psychiatric symptoms and/or lack of social supports.17  
This frustrates time-strapped primary care providers who may already feel uncomfortable 
managing complex psychiatric illness.17  Additionally, somatic symptoms are often attributed 
automatically to psychiatric illness instead of undiagnosed or poorly managed medical illness.4,8   
Therefore, individuals with SMI continue to suffer worse health outcomes and higher mortality 
rates associated with medical illnesses than do people without mental illness even when they 
have access to some medical care in traditional care models.9   
These heath disparities have motivated calls for the integration of behavioral and 
medical health services and a team-based approach to care to overcome barriers to quality 
care, limit the fragmentation of care delivery, and improve physical and mental health 
outcomes.9,11,14,20,21  As a result of the growing body of evidence in support of integration, the 
Affordable Care Act (PL 111-148) has also provided for new funding sources to create such new 
models of care that focus on collaborative care, health maintenance, and preventive care.4  
Whereas this increase in funding has supported the growing body of evidence in support of 
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integrated care for patients diagnosed with depression and comorbid medical illness, there is 
comparatively little assessing the role of integrated care for patients diagnosed with SMI 
(Appendix 1).22–24  Given the demonstrated preference of this patient population for accessing 
psychiatric care over medical care, many proposed integrated care models for persons with SMI 
are designed such that general medical services are co-located or embedded within a mental 
health setting.1,11,14,17  Many of these new models of integrated care also outline a more robust 
role for case management, targeted psychosocial interventions, and increased screening and 
other preventive health services.9,11,17,25      
The approaches to implementing integrated care models and the resulting health 
outcomes have been varied.9,11  One small-scale study at a primary care clinic co-located and 
integrated within a mental health clinic at a VA hospital for patients with SMI found that those 
veterans enrolled in the clinic had higher health care utilization and improved blood pressure, 
LDL cholesterol, triglycerides, and Body Mass Index (BMI).11  However, the majority of 
published works investigating this topic are generally limited in scope, lack capacity for long-
term follow up, report process measures instead of clinically significant physical health 
outcomes, and/or focus predominantly on integrating care for mild to moderate mental illness 
(Appendix 1).8,12,18,23–29  In regard to interventions specific to weight loss and weight 
management, key components of successful weight loss and weight maintenance programs 
designed for patients with SMI are a minimum duration of 4 months, increased frequency of 
face-to-face contact with programming personnel, the use of trained providers to deliver specific 
interventions, and the inclusion of lifestyle modification strategies aimed at improving both 
nutrition and physical activity simultaneously. 1,7,30  Group and individualized interventions aimed 
at preventing weight gain and obesity have also been shown to be effective as well.7,10,31 
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This paper seeks to fill this gap in the existing literature and examine the role that the 
integrated care model of Enhanced Primary Care at the WakeBrook Primary Care Office may 
have in mitigating risks for cardiovascular disease, diabetes, hypertension, and other chronic 
medical illness by improving physical health outcomes.  Thus far, WakeBrook has been 
successful at closing the quality gap by increasing preventive screenings for breast, cervical, 
and colorectal cancers, depression, and falls.2  WakeBrook has also reported improvements in 
chronic disease management outcomes by increasing the percentage of diabetic patients at a 
goal A1c of less than 8% and on preventive statin and/or aspirin therapy.2  Patient reported 
satisfaction scores have also been promising: 94% of patients report “positive” or “very positive” 
perceptions of their care received at WakeBrook.2  However, I aim to examine the effectiveness 
of the current clinical and psychosocial interventions available in this Enhanced Primary Care 
Model and assess whether being enrolled at WakeBrook Primary Care has objectively improved 
long-term physical health outcomes by tracking trends in weight and BMI and rates of obesity.  It 
is my hope that the conclusions and baseline data collected through this study contribute to a 
solid foundation of knowledge that may inform future programming and improve our ability to 
care for this vulnerable patient population. 
Methods  
The WakeBrook Enhanced Model of Primary Care 
 The WakeBrook Primary Care Clinic is a primary care clinic for patients with SMI that is 
co-located with a behavioral health facility in Raleigh, NC.  The Primary Care Office (PCO) 
opened in 2015 with financial support of a Primary and Behavioral Health Care Integration 
(PBHCI) grant program provided by the Substance Abuse and Mental Health Services Agency 
(SAMHSA).2  Patients are referred to the WakeBrook PCO by their behavioral health teams; 
referral criteria include a diagnosis of SMI and not having well-established access to a primary 
care provider.  The model builds on the traditional Patient Center Medical Home (PCMH) model 
with a focus on providing continuous, comprehensive, and coordinated care; WakeBrook is 
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currently rated as a Level 3 PCMH by the National Committee for Quality Assurance.2  In order 
to care for this unique population of medically and socially complex individuals, the Enhanced 
Primary Care Model creates additional time for providers to spend with their patients by capping 
the size of each provider’s patient panel, offers additional training for care team members, and 
supports proactive and structured communication between primary care and behavioral health 
providers.2  As of March 5, 2019, WakeBrook PCO is responsible for the care of 572 patients.   
The clinic is currently staffed by family medicine physicians, a registered nurse, a 
primary care behaviorist with prior training as an addiction specialist (MSW, LCSW, LCAS), a 
case manager (MSW, LCSW), and 2 peer support specialists.2  Each health provider working at 
WakeBrook has had extensive training in treating the SMI patient population.  Furthermore, peer 
support specialists and the primary care behaviorist provide treatment plan support via 
behavioral health counseling, close follow up, and care coordination.  Following the care 
processes submitted in the successful SAMHSA proposal, patients regularly engage with 
clinical personnel and peer support specialists in person or over the phone.  Peer support 
specialists conducted assessments with patients every 6 months in person or over the phone to 
gather supplemental data on social determinants of health, patient satisfaction, and health-
related quality of life.  The peer support specialists and primary care behaviorist also deliver a 
variety of individualized and tailored psychosocial interventions pertaining to self-management 
strategies, substance abuse recovery efforts, chronic disease management, tobacco cessation, 
and nutrition and exercise.  WakeBrook also offers group fitness, yoga, and lifestyle classes to 
patients and to residents in the surrounding community.   
The current approach to weight management, nutrition, and exercise is variable across 
WakeBrook patient population. Clinical and educational interventions are tailored to individual 
patients and heterogenous; some patients receive a combination of one-on-one and group 
counseling and interventions delivered by medical providers, LCSWs, and peer support 
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specialists.  There is no current standardized intervention or protocol for a weight loss or 
management program at WakeBrook Primary Care. 
Study Participants  
 I identified current WakeBrook patients as potential participants in this study by using the 
existing database created to execute the evaluations specified in the SAMHSA grant (hereafter 
referred to as the SAMSHA grant database).  Eligible patients were currently and consistently 
enrolled in the Enhanced Model of Primary Care for a minimum of 18 months as of January 28, 
2019.  Exclusion criteria included inconsistent enrollment or lack of follow up and, because of its 
inevitable influence on weight, pregnancy.  Patients were not eligible if they had been 
discharged from the model at any point during the study period (January 1, 2015 to January 28, 
2019) or were lost to follow up per the SAMHSA grant database records.  As a result, patients 
who did not have any weight data recorded in the Electronic Medical Record (EMR) were also 
excluded.   
Study Design and Data Collection 
 This study was a retrospective chart review.  I recorded the patient enrollment date 
(MM/DD/YY) and calculated the number of complete months that the patient had been 
consistently enrolled in the WakeBrook model as of the censoring date, January 29, 2019, in the 
SAMHSA grant database records.  Number of complete months was also recorded as two 
categories based on distribution of participants: 18 to 22 months or 23 or more complete months 
enrolled.  I abstracted all other data directly from the individual patient’s EMR as recorded 
during clinic visits.  I recorded demographic data, including age (in years), sex (male or female), 
race/ethnicity (Non-Hispanic White, Non-Hispanic Black, Hispanic, or other/not recorded), 
homelessness status (yes or no), and fulltime employment status (yes or no).   
Clinical data recorded included the diagnosis of an ICD-10 code for schizophrenia 
spectrum disorder (yes or no), prescribed at least one atypical antipsychotic (yes or no), 
diagnosis of hypertension (yes or no), diagnosis of dyslipidemia (yes or no), diagnosis of 
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hypertension (yes or no), and height (in meters).  Weight (in kilograms) and height (in meters) 
was also recorded at time of enrollment and at 6-month intervals over the patient’s enrollment 
period for up to 30 months or until the censoring date (January 28, 2019).  BMI was calculated 
for each recorded weight using the formula BMI=kilograms/meters2 and recorded at the same 
time intervals as weight.  Because this study was retrospective, patients did not always follow 
up in-person at exact 6-month intervals, as planned for in an existing protocol.  Therefore, I 
recorded the most recent weight and BMI recorded within that 6-month period.  If the patient 
had not followed up for an in-person clinic visit during a designated 6-month period, no weight or 
BMI was recorded for that interval.  A BMI of 30 kg/m2 or greater is considered obese.32  I 
recorded BMI as a continuous numerical variable (kg/m2), a categorical variable according to 
standard BMI classifications (underweight if BMI less than 18.5, normal weight if BMI is 18.5 to 
<25, overweight if BMI is 25 to <30, class I obesity if BMI is 30 to <35, class II obesity if BMI is 
35 to <40, and class III obesity if 40 or greater), and as a dichotomous variable indicating 
obesity (yes or no) at each 6-month interval.32  Additional information on the variables recorded 
and data collection tool is included in Appendix 2.  It is important to note that I was not able to 
collect data describing the number, types, and content of interventions. 
The University of North Carolina Institutional Review Board determined this study to be 
exempt from further review (IRB 19-0295) and, because this was a chart review study with no 
direct patient contact or follow up, the IRB allowed me to waive informed consent.   
Statistical Analysis 
I calculated summary statistics, including range, distribution, and missingness, to 
evaluate the entire data set and establish baseline patient characteristics (Appendix 3).  When 
appropriate, I used histograms, frequency, percentages, and other descriptive statistics to 
evaluate individual continuous and categorical variables.  In order to evaluate change in weight 
and BMI outcomes over time, I also used repeated paired t-tests to compare baseline mean 
weight and BMI to weight and BMI after 6 months, 12 months, 18 months, 24 months, and 30 
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months of enrollment.  I also compared change in means between intervals.  I set the threshold 
for statistical significance at a p-value of 0.05 for all tests performed in this analysis. 
Because the majority of patients referred to WakeBrook Primary Care had little utilization 
of or access to other primary care prior to enrollment, it is important to attempt to assess 
whether longer time spent enrolled in the model conferred any benefit in terms of weight and 
BMI outcomes.  I first used the Pearson chi-squared test for association to assess for any 
possible association between obesity recorded at the end of the study period and category of 
number of months enrolled in the WakeBrook model (18-22 months or greater than 23 months).  
I then used logistic regression to determine the adjusted magnitude of this association between 
obesity status and long-term enrollment given the potential for confounding.  The fully adjusted 
model included adjustment for confounding by age, gender, race/ethnicity, diagnoses of 
hypertension, type 2 diabetes, dyslipidemia, and/or schizophrenia spectrum disorders, and an 
active prescription for atypical antipsychotics.  I removed race/ethnicity, gender, diagnosis of 
schizophrenia spectrum disorder, and active prescription for atypical antipsychotics in a 
stepwise change-in-estimate approach to produce a reduced, more precise model.  I defined 
significant bias as a change in odds ratio point estimate of 10% or greater.  The resulting final 
model included adjustment for age and comorbid diagnoses of hypertension, Type 2 diabetes, 
and dyslipidemia.  I used STATA 15 for all statistical analyses (STATA Corp, College Station, 
Tx).   
Results 
Participant Characteristics  
 Of the 123 potential participants who were listed as currently enrolled in the WakeBrook 
model of Enhanced Primary Care per the SAMHSA grant database for a minimum of 18 
months, four were determined to be ineligible: two were pregnant during the study period and 
two more were assumed to have been lost to follow-up due to lack of recorded weight data in 
their EMR.  Of the 119 eligible participants, 50.4% have been diagnosed with a schizophrenia 
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spectrum disorder and 68.9% are currently prescribed an atypical antipsychotic (Table 1).  The 
prevalence of other chronic medical illnesses was also high: 61.3% of the study population have 
hypertension, 34.5% have type II diabetes, and 52.9% have dyslipidemia.  At baseline, 59.7% of 
the study population had a BMI of 30 or higher and were categorized as obese.  The average 
weight and BMI at time of enrollment was 97.1 (SD + 26.5) and 33.8 (SD + 9.4) respectively.  
Only 9.5% of patients were recorded as having a full-time job; however, it is important to note 
that these data were not available for 24 of the 119 eligible study participants.  The average 
number of months enrolled in the WakeBrook model was 24.4 (SD + 5.6).  As shown in Table 2, 
those who had been enrolled at WakeBrook for 23 or more months were more likely to be 
female and to have a chronic medical illness (hypertension, diabetes, and/or dyslipidemia).  The 
average number of months enrolled was 29.2 months (SD + 4.1) for the 23-or-more-months 
group and 19.9 (SD + 2.5) for the less-than-23-months group.  In comparison to non-obese 
patients, patients who were obese at time of enrollment, were also more likely to be female and 
to have comorbid medical diagnoses of hypertension, diabetes, and dyslipidemia (Appendix 3, 
Table A3- 2).  However, non-obese patients were more likely to carry a diagnosis of 
schizophrenia spectrum disorder and have an active prescription for an atypical antipsychotic 
than were obese patients at baseline.  Patients who were classified as obese at the end of the 
study period had been enrolled on average for 2.9 more months than were those patients who 
were not classified as obese at the end of the study period.  
Trending Weight and BMI Over Time 
 Overall, the average weight change over the course of the entire study period was a gain 
of 1.69 kg (95% CI -0.21 to 3.60, p-value 0.08).  After 12 months of enrollment, there was a 
statistically significant increase of 2.02 kg in weight (Table 3).  In comparison to the first 6 
months of enrollment, rate of weight gain slowed slightly in the second 6-month interval from 
+1.04 kg over 6 months (95% CI -0.04 to 2.12, p-value 0.06) to +0.98 kg over 6 months (95% CI 
0.06 to 1.90, p-value 0.04).  Mean weights were also relatively lower at the 18 month mark than 
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after the 12 month mark; similarly, mean weight after 24 months was lower than it had been 
after 18 months.  However, these changes were not statistically significant.  The overall trend 
was toward weight gain, as depicted in Figure 1.  The mean weight at time of enrollment was 
97.1 kg (SD + 26.5); mean weight was  98.8 kg (SD + 28.4) at the study end date.   
Mean BMI and change in BMI unsurprisingly followed changes in  weight (Table 4).  The 
data show a statistically significant increase in BMI after 6 months (+0.44 kg/m2, 95% CI 0.02 to 
0.86, p-value= 0.04) and after 12 months (+0.77 kg/m2, 95% CI 0.19 to 1.36).  The rate of 
increase in BMI slowed slightly after 12 months, in comparison to the first 6 months of 
enrollment, to +0.33 kg/m2  (95% CI 0.01 to 0.66, p-value= 0.04).  As shown in Figure 2, there 
was no notable trend in the change of distribution of classification of individuals’ BMI as 
underweight, healthy/normal weight, overweight, class I obesity, class II obesity, and class III 
obesity during the first 18 months of enrollment.  As of the censoring date, 73 participants were 
obese; 71 patients were obese at baseline.  
   
Magnitude of Association between Obesity and Time Enrolled in Enhanced Primary Care Model  
I used Pearson’s chi-squared test of independence and found a statistically significant 
association between recorded obesity at the end of the study period and increased number of 
months enrolled at WakeBrook (chi-squared= 5.17, p= 0.02).  The unadjusted logistic 
regression model shows that enrollment for more than 23 months is associated with a 2.40 
(95% CI 1.12 to 5.15) times greater odds of obesity as of the censoring date than among those 
who were only enrolled for 18 to 22 complete months.  The fully adjusted multivariable 
regression model adjusted for age, gender, race/ethnicity, diagnoses of hypertension, diabetes, 
dyslipidemia, and/or schizophrenia spectrum disorder, and active prescription for atypical 
antipsychotics according to the distribution of patient characteristics (Table 2).  In this fully 
adjusted model, increased time enrolled at WakeBrook is associated with a 2.73 (95% CI 1.05 
to 7.08) times greater odds of obesity.  In the reduced model (adjusting only for age and 
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comorbid medical illness), 23 or more months enrolled at WakeBrook is associated with a 2.49 
(95% CI 1.06 to 5.87) time greater odds of obesity than among patients enrolled for 18 to 22 
months. The approach to this model is summarized in Appendix 3, Table A3-3.   
Discussion 
Limitations 
 The lack of a true comparator population and clearly defined intervention limited the 
strength and significance of this study.  It was my initial hope to be able to compare the trends in 
weight gain and rate of change over time between those patients at WakeBrook who engaged 
with peer support specialists and the clinic’s primary care behaviorist for psychosocial 
interventions surrounding nutrition to those who did not.  I had also originally aimed to collect 
data for the number of face-to-face visits dedicated to these psychosocial interventions in order 
to estimate the dose of exposure.  However, time constraints and delays associated with getting 
IRB approval for more extensive data collection and analysis limited the scope of this project to 
the findings presented here.  The lack of a clearly defined intervention or control group 
introduced significant potential for intervention variability across the study population.  
Therefore, this study was unable to generate conclusions specific to WakeBrook PCO or to the 
current clinical and educational interventions delivered by clinicians and peer support specialists 
within the Enhanced Primary Care Model.   
 As a result of these limitations, time in months was used as a proxy to estimate the level 
of patient exposure to the WakeBrook Enhanced Primary Care Model.  However, time in months 
is not an ideal measurement for dose of exposure without supportive data examining frequency 
or number of patient visits.  For example, those who had been enrolled in the Enhanced Primary 
Care Model for a longer period of time may have been less likely to meaningfully engage with 
clinicians and peer support specialists.  Similarly, those who were documented as being 
enrolled for fewer months might have pursued more frequent contact with WakeBrook staff over 
a shorter period of time.  In both scenarios, the inability to accurately measure the dose of the 
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exposure may have falsely elevated the odds of obesity associated with long-term enrollment 
(Table 5).   
 The strength and significance of this study is also limited by its relatively small sample 
size.  This may have increased the potential for confounding and/or selection bias.  
Furthermore, although data analysis did allow for adjustment for potential confounders.  It is 
difficult to include all of the potential variables that influence and contribute to weight loss and 
gain, especially in the case of a vulnerable patient population with complex social and medical 
histories.  It is particularly difficult to adjust for and quantify the strong role that social 
determinants of health play in physical health outcomes in this population.   
 Other limitations to this study stem from the study design as a retrospective chart study.  
The validity and accuracy of the results and conclusions of this study are based on the 
assumption that each patient’s EMR is accurate and up-to-date, but errors or conflicting data in 
the medical record are possible.  For example, weight and height may have been recorded 
incorrectly by staff during a specific 6- month interval.  Medical staff may have also failed to 
update a patient’s medication or problem list to reflect the most current and up-to-date 
diagnoses and medications.  Such errors may have compromised the validity of the raw data 
collected and the resulting statistical analysis.  This potential for error or discrepancies in the 
data may have also been increased, because the data were not collected according to a 
standardized research protocol.  
 
Implications of Results and Lessons for Future Research  
 The results of this study indicate that sustained weight gain and obesity continue to 
seriously affect the health of patients with SMI despite being enrolled in an Enhanced Primary 
Care Model and establishing a medical home.  From the time of enrollment, WakeBrook 
patients sustained weight gain over the course of this study with no statistically significant 
decrease in rate of weight gain.  After controlling for age and comorbid diagnoses of 
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hypertension, diabetes, and dyslipidemia, patients who had been consistently enrolled in a 
model of Enhanced Primary Care for a longer period of time (> 23 months) were more likely to 
obese than those who had been enrolled for a shorter period of time (18-22 months).  However, 
due to the previously discussed limitations of this study, it is unlikely that the increased odds of 
obesity are the direct result of long-term enrollment at WakeBrook primary care.  Rather, this 
weight gain may be the result of the natural progression of existing chronic disease, medication-
induced weight gain, and complex lifestyle variables that were present prior to being enrolled as 
a patient at WakeBrook.  Therefore, it may be concluded that simply being enrolled in a practice 
with an Enhanced Primary Care Model or establishing a medical home is not sufficient to 
overcome the formidable barriers to weight loss and management that are so common among 
persons with SMI.  Simply put, access to quality primary care does not guarantee improved 
weight and BMI outcomes for patients with SMI; sustained weight loss or management requires 
regular patient engagement with clinically meaningful and evidence-based interventions.   
 Despite study limitations, the findings of this investigation provide vital lessons and 
establish the need for more rigorous research.  The ideal follow up to this study is a prospective 
pre/post intervention study in which patients with SMI and comorbid obesity are compared to 
community controls who have access to a defined standard of usual care and previously 
diagnosed with SMI and obesity.  Ideally, controls should be carefully matched according to 
psychiatric diagnoses, comorbid medical diagnoses, demographic factors, and markers of social 
determinants of health in order to control for confounding.  In contrast to this study, this follow-
up investigation should establish a clearly defined intervention program that is as standardized 
as possible across the study population.  Previously successful weight loss programs often 
combine a variety of interventional approaches in order to address the many factors that 
contribute to weight gain and obesity, prioritizing frequent and longitudinal patient engagement, 
patient education, and lifestyle modification aimed at improving nutrition and level of physical 
activity.1,7,30  This multifactorial intervention approach requires a prospective study in which 
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study personnel working with patients to deliver the interventions follow a previously established 
study protocol that specifies number, general content, and frequency of face-to-face patient 
visits.   
 The existing scholarly literature also indicates that one of the most common weaknesses 
of prior weight loss interventions in the SMI population has been difficulty ensuring follow up 
past 6 months after a structured intervention.1,3  Therefore, the development of an EMR-based 
registry is a vital component of this study design.  This will allow for tracking of patient’s weight 
and BMI over time and track the individual patient progress toward achieving nutrition, exercise, 
and behavioral goals.  An ancillary benefit of developing a comprehensive registry is that it 
could also be utilized to improve quality of care by prospectively identifying those patients at risk 
of developing metabolic syndrome based on upward-trending weight or introduction of a new 
pharmacologic treatment promotes weight gain.  Although this study design and approach 
would be both resource- and time-intensive, it is necessary to investigate potential strategies to 
lessen the serious and complex burden of disease of obesity among patients with SMI.    
 Another potential extension of this investigation would be a qualitative study meant to 
examine the perceptions of barriers and facilitators to weight loss or healthy weight 
maintenance among those patients at WakeBrook.  Rather than evaluating the success or 
failure of a model or specific program, such a qualitative study would aim to provide data and 
supporting information to establish priorities for program improvement or assess perceived 
needs for additional weight management support.  Potential participants would include any 
willing patient who is considered stable mentally and physically by their care providers.  Both 
patients who have been successful with weight loss and/or maintenance and those who have 
struggled with continued weight gain despite documented interventions will be invited to 
participate.  Structured interviews with an established question protocol will permit assessment 
of facilitators and barriers to achieving and maintaining a healthy weight, the level of 
commitment most patients would be willing to make to achieve desired weight outcomes, and 
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the specific components of prior interventions patients found to be most helpful.  Interviews 
would be recorded, transcribed, and coded to identify common themes and perceptions of 
weight loss program components.  In the case of WakeBrook where the current approach to 
weight management interventions is heterogenous and individualized, a qualitative study would 
allow for a greater appreciation of the individual components of healthy weight initiatives that are 
perceived to be the most effective.   
 
Conclusion 
 Individuals with Severe Mental Illness have shorter life expectancies, higher morbidity 
and mortality rates associated with chronic medical conditions, and limited access to and benefit 
from quality primary care.  In response to these health disparities, the WakeBrook Primary Care 
Office opened in 2015 at a mental health facility in Raleigh, NC.  Through the clinic’s Enhanced 
Primary Care Model, WakeBrook has succeeded in improving health care quality outcomes for 
their patient population, all of whom have been diagnosed with SMI and previously did not have 
consistent access to quality primary care.   
As expected, this retrospective chart review of patients with SMI found high rates of 
hypertension, diabetes, dyslipidemia, and obesity among a subset of WakeBrook Primary Care 
patients.  This study’s results also demonstrate that enrollment in WakeBrook for a minimum of 
18 months did not lead to weight loss or any significant decrease in rate of weight gain.  As a 
result, it can be concluded that merely being assigned to a medical home or practice with an 
enhanced model of primary care is not sufficient to overcome the tremendous barriers to 
achieving sustained weight loss.  However, study design, limitations, and scope failed to 
adequately assess the effectiveness of current WakeBrook clinical and education interventions 
at lessening the burden of obesity and weight gain in comparison to usual care.  Nonetheless, 
the findings of this study do provide the necessary preliminary data to support a more robust 
and resource-intensive follow-up study in which a clearly-defined intervention group of patients 
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diagnosed with SMI is carefully compared and matched to a control group.  Any future 
investigation should also prioritize the development of robust systems of measurement required 
for data collection, analysis, and follow up.  A follow-up qualitative study may also be helpful to 
assess patient perception of current weight management programs.  This expanded research 
scope has the potential to generate data necessary to garner the support and funding required 
for current program expansion or implementation of new programming aimed at improving the 
physical health of persons diagnosed with SMI.   
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Table 1: Characteristics of Study Participants at Time of Enrollment 
  Total Cohort 
N=119 
  Percent (n) 
Gender 
 
    Male 44.5 (53) 
Female 55.5 (66) 
Race/Ethnicity 
 
    White, Non-Hispanic 37.0 (44) 
    Black, Non-Hispanic 52.9 (63) 
    Hispanic/Latino 3.4 (4) 
Other/Not Recorded 6.7 (8) 
Diagnosis of Hypertension 61.3 (73) 
Diagnosis of Diabetes 34.5 (41) 
Diagnosis of Dyslipidemia 52.9 (63) 
Homeless 9.3 (11) 
Full-time employment  9.5 (9) 
Diagnosis of Schizophrenia 
Spectrum Disorder 
50.4 (60) 
Prescribed Atypical Antipsychotics 68.9 (82) 
BMI classification at baseline 
 
     Underweight (< 18.5) 1.7 (2) 
     Healthy Weight (18.5 to < 25) 16.8 (20) 
     Overweight (25 to < 30) 21.9 (26) 
     Class I Obesity (30 to < 35) 21.0 (25) 
     Class II Obesity (35 to < 40) 14.2 (17) 
Class III Obesity (> 40) 24.4 (29) 
  Mean (SD) 
Age in years 51.5 (12.1) 
Number of months enrolled in 
Enhanced Primary Care Model  
24.4 (5.6) 
Weight at time of enrollment (kg) 97.1 (26.5) 
BMI at time of enrollment (kg/m2) 33.8 (9.4) 
Height 1.69 (0.11) 
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Table 2: Characteristics of Study Population According to Amount of Time Enrolled  
Enrolled for 18-22 
Months 
n= 62 
Enrolled for > 23 
months 
n= 57 
  Percent (n) 
Gender 
 
    Male 48.4 (30) 40.4 (23) 
Female 51.6 (32) 59.7 (34) 
Race/Ethnicity 
 
    White, Non-Hispanic 37.1 (23) 36.8 (21) 
    Black, Non-Hispanic 51.6 (32) 54.4 (31) 
    Hispanic/Latino 1.6 (1) 5.3 (3) 
Other/Not Recorded 9.7 (6) 3.5 (2) 
Diagnosis of Hypertension 53.2 (33) 70.2 (40) 
Diagnosis of Diabetes 22.6 (14) 47.4 (27) 
Diagnosis of Dyslipidemia 43.6 (27) 63.2 (36) 
Homeless 11.5 (7) 7.0 (4) 
Full-time employment  10.2 (5) 8.7 (4) 
Diagnosis of Schizophrenia 
Spectrum Disorder 
51.6 (32) 49.1 (28) 
Prescribed Atypical Antipsychotics 69.4 (43) 68.4 (39) 
Obese at study censor date (BMI > 
30) 
51.6 (32) 71.9 (41) 
  Mean (SD) 
Age in years 50.0 (12.7) 53.1 (11.32) 
Number of months enrolled in 
Enhanced Primary care Model  
19.9 (1.5) 29.2 (4.1) 
Weight at study censor date (kg) 98.8 (32.9) 98.9 (22.8) 
BMI at study censor date (kg/m2) 34.5 (12.1) 34.5 (7.6) 
Height 1.70 (0.11) 1.70 (0.11) 
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Table 3: Mean Change in Weight Over Time 
Time (mos) 
n=119 
Mean Weight (kg)  
(SD) 
Mean Change from 
Baseline (kg) (95% 
CI) 
Mean Change from 
prior 6-month 
interval (kg) 
(95%CI) 
Baseline (t=0) 
n=119 97.1 (26.5) -- -- 
6 
n=118 98.1 (27.1) 
+1.04 (-0.04 to 2.12) 
p=0.06 -- 
12 
n=117 99.4 (28.5) 
+2.02 (0.47 to 3.58) 
p=0.01 
+0.98 (0.06 to 1.90) 
p=0.04 
18 
n=117 98.4 (27.7) 
+1.34 (-0.24 to 2.93) 
p=0.10 
-0.42 (-1.29 to 0.46) 
p=0.35 
24 
n=47 99.1 (22.0) 
+2.22 (-0.73 to  5.18) 
p=0.14 
-0.06 (-1.53 to 1.40) 
p=0.93 
30 
n=26 101.1 (24.2) 
+2.46 (-1.31 to 8.84) 
p=0.14 
+0.52 (-1.70 to 2.74) 
p=0.63 
Censor Date 
(01/29/2019) 
n=119 
98.8 (28.4) +1.69 (-0.21 to 3.60) p=0.08 -- 
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Figure 1: Mean Recorded Weight in Kilograms Over Time 
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Table 4: Mean Change in BMI Over Time 
Time (mos) 
n=119 
Mean BMI (kg/m2)  
(SD) 
Mean Change from 
Baseline (kg/m2) 
(95% CI) 
Mean Change from 
prior 6-month 
interval (kg/m2) 
(95%CI) 
Baseline(t=0) 
n=119 33.8 (9.4) -- -- 
6 
n=118 34.4 (9.6) 
+0.44 (0.02 to 0.86) 
p=0.04 -- 
12 
n=117 34.7 (10.1) 
+0.77 (0.19 to 1.36) 
p=0.01 
+0.33 (0.01 to 0.66) 
p=0.04 
18 
n=117 34.4(10.0) 
+0.54 (-0.06 to 1.14) 
p=0.07 
-0.14 (-0.44 to 0.15) 
p=0.34 
24 
n=47 34.5 (7.1) 
+0.73 (-0.29 to  1.76) 
p=0.16 
+0.004 (-0.51 to 
0.52) p=0.99 
30 
n=26 35.1 (7.2) 
+1.33 (-0.51 to 3.17) 
p=0.15 
+0.20 (-0.62 to 1.01) 
p=0.63 
Censor date 
(01/28/2019) 
n=119  
34.5 (10.1) +0.67 (-0.03 to 1.37) p=0.06 -- 
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Figure 2: Change in BMI Classification Distribution from 0 to 18 Months 
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Table 5. Association between Obesity and Number of Months Enrolled in Enhanced 
Primary Care Model as of Study Censoring Date (01/28/2019) 
Model Obese (BMI> 30) vs. Not Obese 
OR (95% Confidence interval) 
p-value 
Unadjusted  2.40 (95% CI 1.12 to 5.15) 0.02 
Fully adjusted* 2.73 (95% CI 1.05 to 7.08) 0.00 
Final model†  2.49 (95% CI 1.06 to 5.87) 0.01 
*Model Controls for age, gender, race/ethnicity, diagnoses of hypertension, diabetes, 
dyslipidemia, and/or schizophrenia spectrum disorders, and active prescription for atypical 
antipsychotics 
†Model controls for age and comorbid diagnoses of hypertension, diabetes, and dyslipidemia 
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Appendix 1: Limited Systematic Review 
Introduction 
 Among persons with Severe Mental Illness (SMI), rates of chronic illnesses, such as 
cardiovascular disease and diabetes, are much higher.2,11,17 Furthermore, the quality of care 
received by these patients with SMI is generally poor, because those with SMI have a tendency 
to primarily seek care for their mental illness and medical and mental health providers are often 
ill-equipped to navigate such complex patients within traditional health care delivery 
models.11,14,17  Suboptimal care has led to poor physical health outcomes and disproportionately 
high mortality rates from preventable conditions for the SMI population.1,4,6 As a result, there 
have been calls for increased integration between mental health services and primary care in 
health care literature, leading to the formation of new integrated models of care specifically 
targeting patients with mental illness. 11,16,17 The goal of this limited systematic review is to 
assess the success of these new integrated models of care at improving overall specific 
physical health and disease outcomes for those with SMI.  Therefore, the key research question 
is:  
What are the physical health outcomes in terms of obesity, diabetes, and cardiovascular 
disease associated with implementation of and access to integrated behavioral health 
and primary care models for patients with Severe Mental Illness? 
For the purposes of this review, integrated care will include a care model in which health care 
workers providing mental and behavioral health services collaborate with those providing 
medical services.  This includes mental health services embedded in primary care practice and 
the “reverse integration” care models in which primary care is co-located within a mental health 
practice or setting.17   
Methods 
 The population of interest for this literature search was adult patients with SMI.  For the 
scope of this review, SMI was defined as a diagnosable mental, behavioral, or emotional 
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disorder that causes serious functional impairment and interferes with major life activities.2  Most 
commonly, this includes diagnoses of schizophrenia spectrum disorders, bipolar disorder, or 
depression with psychotic features.  In general, this is a broader definition than others 
commonly used in the literature but was selected for consistency with prior literature discussing 
the WakeBrook Enhanced model of Primary Care and acknowledgement of the importance of 
functional status is defining mental illness as severe.  Studies examining interventions for those 
with mild to moderate mental illness were not considered for this review. The intervention of 
interest for this review was implementation of an integrated care model versus usual care in a 
traditional care delivery model.  Primary outcomes of interest were any physical and objective 
health outcomes related to obesity, diabetes, and cardiovascular health, such as weight, BMI, 
hemoglobin A1c, and blood pressure.  With these as the primary outcomes of interest, potential 
study designs include randomized control trials, case studies, case-control studies, and both 
retrospective and prospective cohort studies.  Systematic reviews, model proposals, and 
research protocols were excluded.  
 I first identified relevant articles via a search of published articles included in the PubMed 
database.  Search terms and general- search strategy was developed with the aid of a 
graduate-trained librarian.  The search terms used were: (mental disorders[majr] OR "Mental 
Health Services"[Majr] OR mental health[majr] OR "mental health"[tiab] OR mental[tiab] OR 
behavior*[tiab] OR behaviour*[tiab] OR psychiatric[tiab]) AND ("primary care"[tiab] OR "primary 
health"[tiab] OR "primary healthcare"[tiab] OR primary health care[mesh] OR "community 
health"[tiab] OR "community healthcare"[tiab] OR phc[tiab]) AND ("Delivery of Health Care, 
Integrated"[Majr] OR integrat* OR embed* OR collaborat* OR partner* OR team*) AND ("weight 
management”[Majr] OR “diabetes”[tiab] OR “cardiovascular disease”[tiab]) AND (severe[tiab] 
OR serious[tiab] OR major[tiab] OR schizophreni* OR schizophrenia OR bipolar OR depression 
OR psychosis OR psychotic[tiab] OR Bipolar and Related Disorders[majr]).  A filter was applied 
to only include full-text articles published in English within the past ten years (since 2009).  As 
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this review only considers published works, studies still in-progress were not considered. I 
conducted this search on April 12,2019.   
 Following this search, I independently reviewed all article titles and abstracts for 
appropriateness and relevance to this review’s research question using Covidence.33  Those 
deemed relevant per eligibility criteria were then included for a full text review for final inclusion 
for data abstraction.  Full-text articles were assessed for appropriateness for inclusion based on 
study population and demographics, intervention, comparison, outcome, timing, and study 
design.  Eligibility criteria are outlined in PICOTSS format in Table A1-1.  Articles determined to 
be appropriate were then critically appraised for risk of bias, external validity, and overall quality 
using the framework provided from PUBH 751: Critical Appraisal of the Health Literature class 
at the UNC Gillings School of Global Public Health.  I determined overall risk of bias as low, 
medium, or high according to the study’s potential for selection bias, measurement bias, and 
confounding.  External validity was rated as poor, fair, good, or excellent. Each article then 
received an overall quality rating of poor, fair, good, or excellent as a result of this appraisal.  
Data were extracted from each article and then prepared for a descriptive summary.  Data 
collected includes including individual study characteristics, study population and participant 
characteristics, description of intervention, outcomes measured and reported, and key 
conclusions 
Results  
Search Strategy 
 The PubMed search yielded 236 articles.  Screening of titles and abstracts resulted in 
204 studies being deemed as irrelevant and 32 full-text studies being considered for eligibility.  
Twenty-nine of these 32 articles were then excluded based on outcomes, study design, and 
patient population.  Of note, I excluded many of the articles after full text review, because they 
had too narrow of a study population and specifically excluded patients with schizophrenia 
spectrum disorders, bipolar disorder, and/or psychosis.  One study focused on integrated care 
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for patients diagnosed with depression was still included in this review, because major 
depressive disorder with psychosis is a common diagnosis for SMI patients;  this study also did 
not enumerate specific eligibility criteria that would have excluded patients with schizophrenia, 
bipolar, and/or psychosis.  The resulting three articles were then included in this limited 
systematic review for data extraction.  The results of this search strategy are summarized in 
Figure A1-1 in a PRISMA diagram.  
Study Characteristics and Results  
 In a pilot randomized control trial, Chwastiak et al. examined the effect of adapting the 
TEAMcare model previously designed for patients with depression and diabetes to a 
Community Mental Health Center (CMHC) setting for diabetic patients with SMI (Table A1-2).34  
This care model centered around the utilization of a nurse care manager who met weekly with 
intervention-group patients weekly for 12 weeks followed by monthly meetings for up to 6 
months.  This model of care also emphasized a team-based approach to care with nurse care 
managers, psychiatrists, Advanced Practice Registered Nurses (APRN), and consulting 
endocrinologist all developing care plans for individual patients together.  In comparison to usual 
care study participants who continued to receive standard mental health treatment at the 
CMHC, collaborative care patients had greater decrease in average HbA1c (-1.1%, 95% CI -
2.20 to -0.02, p=0.049) and  BMI (-1 kg/m2 , 95% CI -1.80 to 0.010, p=0.04).  There was no 
statistically significant change in LDL cholesterol, triglycerides, or systolic blood pressure.  
However, the weight and significance of these results is limited by the overall poor-quality rating 
of this study due to this study’s limited small sample size of only 35 participants (Table A1-3).  
 However, Pirraglia et al. was rated as fair overall quality and had similar findings in a 
pre/post intervention study amongst veterans with SMI, at least one concurrent chronic medical 
condition, and demonstrated poor access to primary care (Table A1-2, Table A1-3).11  In this 
study, eligible veterans were referred to care at the Serious Mental Illness Primary Care Clinic 
(SMIPCC), a primary care clinic co-located with the mental health outpatient clinic.  When 
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possible, behavioral health and medical health teams also tried to coordinate scheduling of 
primary care and mental health visits on the same day.  In comparison to pre-enrollment, the 
adjusted odds ratio of achieving a goal blood pressure of less than 140/90 mmHg for general 
patients or 130/90 for diabetic patients was 2.16 (95% CI 1.47 to 3.18).  There were also 
improved odds of achieving goal an LDL cholesterol level less than 130 mg/dL (1.60, 95% CI 
1.10 to 2.34), triglycerides less than 150 mg/dL (1.64, 95% CI 1.06 to 2.51), and BMI less than 
30 kg/m2 (1.81, 95% CI 1.29 to 2.54).   
 Last, Rossom et al. was a longitudinal cohort study of good quality that looked at the 
effect of collaborative care for patients diagnosed with depression and diabetes of 
cardiovascular disease at 172 clinics across 18 different health care systems in the United 
States (Table A1-2, Table A1-3).35  With the model used in this intervention, care managers, 
primary care providers, and psychiatrists collaborated in a treat-to-target approach.  One key 
component to this intervention was that care team members met weekly for systematic case 
reviews to monitor and intensify treatment plans for patients who were struggling to meet 
specific goals.  At the end of the study period, 23% of patients who had a HbA1c greater than 
8.0% had achieve glucose control (defined as a HbA1c less than 8.0%); 58% of patients with 
heart disease and a blood pressure higher than 140/90 mmHg achieved blood pressure control 
(defined as less than 140/90 mmHg).  This study also found that those who had been enrolled 
for fewer than 3 months had lower rates of glucose or blood pressure control.  Although I rated 
this study as having overall good quality, the results may have limited applicability to answer the 
key question of this review and inform the care specifically of patients with SMI, because it only 
addressed care for patients with depression.  
Risk of Bias 
 The risk of bias for the three articles included in this review ranged from low to medium-
high due to potential for selection bias, measurement bias, and confounding (Table A1-3). For 
example, Chwastiak et al., had a medium risk for selection bias and high potential for 
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confounding due to the study’s small sample size and randomization process for an over 
medium-high risk of bias.  The article outlines a process through which the study’s 35 
participants were randomized 1:1 to either usual care or the intervention group and stratified 
based on treatment with insulin, clozapine, or olanzapine at baseline.34  The article also states 
that there was no statistically significant difference in the demographic or clinical characteristics 
of the two treatment groups.  However, the online supplement showed that more patients in the 
usual care group were on second generation antipsychotics than the intervention group (70.6% 
vs. 38.9%).  The intervention group also had a higher baseline A1c (9.4% vs. 8.3%) and BMI 
(37.5 vs. 35.2) than the usual care group.34    This may have resulted in bias away from the null, 
because the potential for improvement was greater amongst the intervention group.   
The Pirraglia et al. article had an overall medium risk of bias introduced by a small 
sample size and loss to follow up.  For example, there were only nine observations recorded for 
HbA1c level during the second 6-month time interval in this study.11  The article also did not give 
any information on those patients who had been lost to follow up in comparison to those for 
whom data gathered was gathered throughout the entire study period. The data analysis 
methods for this study were appropriate and allowed for sufficient control for potential 
confounders.11  However, there was also concern for measurement bias due to the choice of 
researchers to dichotomize outcomes as either “at goal” or not versus reporting outcomes in 
terms of actual numerical change.  This may have led to overestimation of the true effect of the 
integrated care model and makes it difficult to compare the relative success of this model to 
others.   
The Rossom et al. article also reported outcomes in a similar way, thus potentially 
limiting the strength of the studies’ conclusions.28  There was also concern for measurement 
bias due to the lack of standardized intervention across different clinical sites.  This concern is 
supported by the study’s findings that outcomes varied significantly across different medical 
groups.28   Despite this potential for measurement bias, I assessed the overall risk of bias to be 
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low.  The study design, sample size, and data analysis were all sound and there was little 
potential for bias due to selection bias or confounding.28     
Discussion  
 Overall, each of the studies included in this review reported some level of improvement 
in physical health outcomes related to diabetes, obesity, and/or cardiovascular disease for those 
patients with SMI enrolled in innovative care models integrating behavioral and medical health 
care services.  Studies differed according to site, patient population, time, study design, and 
intervention protocols.  Although interventions and results varied across each study, each 
intervention included a team-based approach to care with multiple care providers contributing to 
the treatment plans for individual patients.  Each intervention also attempted to build a strong 
foundation in enhanced communication between different levels of care.   
 Limitations to this review are largely related to the quality, scope, and sample size of 
studies included.  Two studies, Chwastiak et al. and Pirraglia et al, were the most appropriate to 
answer the key question of this review; however, these studies also had small sample sizes and 
substantial concerns for bias.  The external variability and significance of results of these 
studies were also limited.  It is unclear whether the results reported in these studies would be 
applicable to larger populations outside of the specific study settings (a CMHC and outpatient 
VA mental health clinic).11,34  This review was also limited by the fact that I was the sole 
independent reviewer.  The methods were not repeated by a second independent reviewer; 
therefore, there is potential for selection bias that may have emerged in the process of 
evaluating articles for inclusion.  
 In the completion of this review, certain gaps in the literature were very clear; the 
majority of published literature assessing the effects of integrated care focus primarily on the 
management of mild to moderate mental illness with comorbid medical illness, such as 
diabetes.  Despite the higher morbidity and mortality due to chronic medical illnesses, there is 
comparatively very little literature examining physical health outcomes associated with 
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integrated care models and the care of individuals with SMI.  If health care systems hope to 
address the profound disparities in health outcomes and health care quality, more quality, large 
scale research is needed to ensure that we are able to provide patients with SMI with the 
comprehensive medical care that they need and deserve.  
Conclusion  
 Despite the many calls for integration of medical and behavioral health care for those 
suffering from Serious Mental Illness, there are still few studies that examine the effect of 
integrated and collaborative care models on the physical health outcomes of SMI patients.  
While limited by scope and quality, the results of this limited systematic review suggest that 
such integrated care models may have the potential to close the existing gap in health 
outcomes.  However, more extensive research is needed to design future interventions and care 
models specifically tailored to this unique patient population. 
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Table A1-1: PICOTSS Eligibility Criteria for Title and Abstract Review  
Criteria Inclusion  Exclusion  
Population Adult patients (> 18 years-
old, patients diagnosed with 
Severe Mental Illness 
Pediatric patients (< 18 
years-old), includes only 
patients diagnosed mild to 
moderate mental illness (i.e. 
study specifically excludes 
participants diagnosed with 
schizophrenia spectrum 
disorders, bipolar, and/or 
psychosis) 
Intervention Integrated medical care and 
behavioral care model 
No collaborative care model 
in place, standard/ usual care  
Comparison None or Standard care/ usual 
care in a traditional care 
model  
- 
Outcome Weight and BMI, Diabetes, 
and/or Cardiovascular 
disease physical health 
outcomes  
No physical outcomes , 
quality measures, screening 
rates  
Timing No Time Restriction  - 
Setting Only studies conducted in the 
United States within the past 
10 years  
Studies conducted in other 
countries and/or prior to April 
2, 2019 
Study Design  English, Full-text, 
Retrospective + prospective 
cohort studies, case-control, 
case series, RCTs, 
observational studies 
Non-English, abstract only, 
Systematic Reviews, Meta-
analysis, Research protocol, 
model proposals 
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Figure A1-1: PRISMA Flow diagram  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 38 
 
Table A1-2 : Study Characteristics and Outcomes 
 Chwastiak et al., 2018 Rossom et al., 2017 Pirraglia et al., 2012 
Title Use of A Mental Health  
Center Collaborative 
Care Team to Improve 
Diabetes Care and 
Outcomes for Patients 
with Psychosis  
Impact of a National 
Collaborative Care 
Initiative for Patients 
with Depression and 
Diabetes or 
Cardiovascular Disease 
Benefits of a Primary 
Care Clinic Co-
Located and 
Integrated in a Mental 
Health Setting for 
Veterans with Serious 
Mental Illness 
Study 
Design 
Pilot Randomized Control 
Trial 
Longitudinal Cohort 
Study 
Pre/Post Intervention 
Study 
Study 
Population  
 
Clinic patients ages 18-
64 with a primary 
diagnosis of 
schizophrenia, 
schizoaffective disorder, 
bipolar disorder, or 
majority depressive 
disorder with psychosis 
who are also diagnosed 
with T2DM, have a 
HbA1c >8% or blood 
pressure> 140/90, and 
the ability to read English 
(n=35) 
Patients with active 
depression and 
comorbid diabetes 
and/or CVD who were 
consistently  enrolled in 
the COMPASS model 
for at least 1 month 
between February 
2013-March 2015  
 
(n=3609) 
Veterans with chronic 
and active mental 
health conditions who 
have been enrolled at 
the SMIPCC for at 
least 1 year, 
diagnosed with at 
least 1 concurrent 
chronic medical 
condition, and 
demonstrated poor 
access to primary 
care. 
 
(n=97) 
Setting 
 
2 Community Mental 
Health Centers in King 
County, Washington 
172 clinics across 18 
different care systems in 
the United States 
Providence VA 
Medical Center 
Intervention  
 
Adapted TEAMcare 
Model: CMHC-based 
collaborative care for 
diabetes with weekly 
contact with care 
managers for 12 weeks 
followed by monthly for 
up to 6 months 
Adapted COMPASS 
model: Collaborative 
care teams with care 
managers, consulting 
primacy care providers, 
and psychiatrist with no 
standardized length of 
program and treat-to-
target guidelines 
Enrollment in the 
SMIPCC, a primary 
care clinic co-located 
and integrated in the 
mental health 
outpatient program 
Outcome(s) 
 
At 3 months follow-up 
HbA1c:  
-1.1% (-2.20 to -0.01 
95% CI, p=0.049) change 
in collaborative care 
patients versus -0.40% (-
1.20 to 0.40 95%CI, 
p=.30) in usual care 
BMI: -1 kg/m2 (-1.80 to -
0.10, p=0.04) and -0.9 
kg/m2 (-1.70 to -0.02, 
At end of Study Period  
Glucose control: 23% of 
patients with a 
HbA1c>8.0% at time of 
enrollment achieved 
glucose control (defined 
as HbA1c<8.0%), 
patients enrolled for less 
than 3 months had 
lower rates of glucose 
control than those who 
After 6 months of 
enrollment (in 
comparison to at time 
of enrollment) 
Blood Pressure: AOR 
for achieving blood 
pressure <140/90 for 
general patients or 
<130/80 for patients 
with diabetes= 2.16 
(1.47 to 3.18 95% CI) 
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p=0.04) change in the 
intervention and usual 
care groups respectively. 
*No statistically 
significant change in LDL 
cholesterol, Triglycerides, 
or Systolic Blood 
Pressure in either group. 
were enrolled for 6-9, 9-
12, 12-15, or 15-18 
months 
Blood Pressure Control:  
58% of patients 
diagnosed with heart 
disease and blood 
pressures > 140/90 
mmHg achieved blood 
pressure control 
(defined as blood 
pressure <140/90 
mmHg), patients 
enrolled for less than 3 
months had lower rates 
of control than those 
who were enrolled for 3-
6, 6-9, 9-12, 12-15, or 
15-18 months 
LDL Cholesterol: AOR 
for achieving LDL<130 
mg/dL= 1.60 (1.10 to 
2.34 95% CI) 
Triglycerides: AOR for 
achieving triglycerides 
<150 mg/dL= 1.64 
(1.06-2.51 95% CI) 
BMI:AOR for 
achieving BMI< 30 
kg/m2 = 1.81 (95% CI 
1.29 to 2.54) 
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Table A1-3: Risk of Bias, External Validity and Overall Quality Rating 
Study Selection 
Bias 
Measurement 
Bias 
Potential for 
Confounding 
Overall 
Risk of 
bias 
External 
Validity 
Quality 
Rating 
Chwastiak 
et al., 
2018 
Medium Low High Medium-
High 
Poor Poor 
Rossom 
et al., 
2017 
Low Medium Low Low Good Good 
Pirraglia 
et al., 
2012 
Medium Medium Low Medium Fair Fair 
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Appendix 2: Extended Methods: Data Collection Tool and Variables  
 
Figure A2-1: Illustration of Data Collection Tool  
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Table A2-1: Codebook and Description of Variables  
Variable Label Description 
id Study ID Randomly assigned study ID, Continuous, 0-1000 
start Enrollment date The date patient is listed as enrolling in the 
WakeBrook Enhanced Primary Care Model in the 
SAMHSA grant database, MM/DD/YY 
mos Total Number of total 
months enrolled as of 
01/28/2019 
Number of complete months consistently enrolled 
in SAMHSA grant, includes at a minimum of 
survey feedback every 6 months during time of 
enrollment 
In months, Continuous 
mocat Number of total months 
enrolled as of 01/28/2019 
in categories 
Generated by STATA to transform “mos” 
continuous variable into approximately equal 
categories 
0= 18 to 22 complete months 
1= 23 or more complete months 
 
age Age In years, Continuous 
gen Gender M=0 F=1, Dichotomous 
raceth Race/Ethnicity Race/ Ethnicity as recorded in demographic data 
in electronic medical record 
1= White/ Non-Hispanic Latino 
2= Black, African American 
3= Hispanic/Latino 
4= Other/ Not recorded, 
Categorical 
dx Diagnosis of 
Schizophrenia Spectrum 
Disorder* 
Patient is recorded as being diagnosed with a 
schizophrenia spectrum disorder in the problem list 
in the EMR 
Y=1 N=0, Dichotomous  
meds Prescribed atypical 
antipsychotics** 
Patient is recorded as having an active 
prescription for at least one atypical antipsychotic 
in the EMR 
Y= 1 N=0, Dichotomous 
kgt0 Weight at enrollment (kg) Weight at time of enrollment (t=0 months) in 
kilograms, Continuous  
kgt6 Weight at 6 mos (kg) Most recent weight recorded in electronic medical 
record during the 6-month interval from 1 to 6 
complete months of enrollment, in kilograms, 
Continuous 
kgt12 Weight at 12 mos (kg) Most recent weight recorded in electronic medical 
record during the 6-month interval from 7 to 12 
complete months of enrollment, in kilograms, 
Continuous 
kgt18 Weight at 18 mos (kg) Most recent weight recorded in electronic medical 
record during the 6-month interval from 13 to 18 
complete months of enrollment, in kilograms, 
Continuous 
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kgt24 Weight at 24 mos (kg) Most recent weight recorded in electronic medical 
record during the 6-month interval from 19 to 24 
complete months of enrollment, in kilograms, 
Continuous 
kgt30 Weight at 30 mos (kg) Most recent weight recorded in electronic medical 
record during the 6-month interval from 25 to 30 
complete months of enrollment, in kilograms, 
Continuous 
kgend Weight at the end of study 
period/ censor date of 
01/28/2019 (kg) 
Most recent weight recorded as a part of this 
study, in kilograms, continuous 
height Height (m) Patient height as recorded at time of enrollment, in 
meters, Continuous 
bmit0 BMI at enrollment (kg/m2) BMI at time of enrollment in SAMHSA grant study, 
calculated variable as weight in kilograms divided 
by height in meters squared (kg/m2), Continuous 
bmit6 BMI at 6 mos 
(kg/m2) 
Most recent BMI during the 6-month interval from 1 
to 6 complete months of enrollment, in kg/m2, 
Continuous 
bmit12 BMI at 12 mos 
(kg/m2) 
Most recent BMI during the 6-month interval from 7 
to 12 complete months of enrollment, in kg/m2, 
Continuous 
bmit18 BMI at 18 mos 
(kg/m2) 
Most recent BMI during the 6-month interval from 
13 to 18 complete months of enrollment, in kg/m2, 
Continuous 
bmit24 BMI at 24 mos 
(kg/m2) 
Most recent BMI during the 6-month interval from 
19 to 24 complete months of enrollment, in kg/m2, 
Continuous 
bmit30 BMI at 30 mos 
(kg/m2) 
Most recent BMI during the 6-month interval from 
25 to 30 complete months of enrollment, in kg/m2, 
Continuous 
bmiend BMI at the end of study 
period/ censor date 
01/28/2019 
(kg/m2) 
Most recent BMI recorded as a part of this study, 
in in kg/m2, Continuous 
diab Diagnosis of type 2 
diabetes 
Diagnosis of Diabetes Mellitus, type 2 as listed in 
patient problem list in chart 
Y=1 N=0, 
Dichotomous 
htn Diagnosis Hypertension 
Y=1 N=0 
Diagnosis of Hypertension as listed in patient 
problem list in chart 
Y=1 N=0, 
Dichotomous 
lipid Dyslipidemia Any diagnosis of dyslipidemia as listed in patient 
problem list in chart 
Y=1 N=0, 
Dichotomous 
home Homeless? Patient listed as homeless in demographics 
section in chart 
Y=1 N=0, 
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Dichotomous 
employ Employment? Patient listed as having full time employment in 
demographics section in chart 
Y=1 N=0, 
Dichotomous 
bmicatt0 BMI Classification at time 
of enrollment 
Generated by STATA to transform “bmit0” 
0=underweight 
1= normal/healthy weight 
2= overweight 
3= class I obesity 
4= class II obesity 
5= class III obesity, Categorical 
bmicatt6 BMI Classification after 6 
months 
Generated by STATA to transform “bmit6” 
0=underweight 
1= normal/healthy weight 
2= overweight 
3= class I obesity 
4= class II obesity 
5= class III obesity, Categorical 
bmicatt12 BMI Classification after 12 
months 
Generated by STATA to transform “bmit12” 
0=underweight 
1= normal/healthy weight 
2= overweight 
3= class I obesity 
4= class II obesity 
5= class III obesity, Categorical 
bmicatt18 BMI Classification after 18 
months 
Generated by STATA to transform “bmit12” 
0=underweight 
1= normal/healthy weight 
2= overweight 
3= class I obesity 
4= class II obesity 
5= class III obesity, Categorical 
bmicatt24 BMI Classification after 24 
months 
Generated by STATA to transform “bmit24” 
0=underweight 
1= normal/healthy weight 
2= overweight 
3= class I obesity 
4= class II obesity 
5= class III obesity, Categorical 
bmicatt30 BMI classification after 30 
months 
Generated by STATA to transform “bmit30” 
0=underweight 
1= normal/healthy weight 
2= overweight 
3= class I obesity 
4= class II obesity 
5= class III obesity, Categorical 
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bmicatend BMI classification at end of 
study period/ censor date 
01/28/2019 
Generated by STATA to transform “bmiend” 
0=underweight 
1= normal/healthy weight 
2= overweight 
3= class I obesity 
4= class II obesity 
5= class III obesity, Categorical 
obeset0 Patient classified as obese 
at time of enrollment 
Generated by STATA to transform “bmit0” if BMI 
greater than or equal to 30 kg/m2 at that time 
Y=1 N=0, Dichotomous 
obeset6 Patient classified as obese 
after 6 months 
Generated by STATA to transform “bmit6” if BMI 
greater than or equal to 30 kg/m2 at that time 
Y=1 N=0, Dichotomous 
obeset12 Patient classified as obese 
after 12 months 
Generated by STATA to transform “bmit12” if BMI 
greater than or equal to 30 kg/m2 at that time 
Y=1 N=0, Dichotomous 
obeset18 Patient classified as obese 
after 18 months 
Generated by STATA to transform “bmit18” if BMI 
greater than or equal to 30 kg/m2 at that time 
Y=1 N=0, Dichotomous 
obeset24 Patient classified as obese 
after 24 months 
Generated by STATA to transform “bmit24” if BMI 
greater than or equal to 30 kg/m2 at that time 
Y=1 N=0, Dichotomous 
obeset30 Patient classified as obese 
after 30 months 
Generated by STATA to transform “bmit30” if BMI 
greater than or equal to 30 kg/m2 at that time 
Y=1 N=0, Dichotomous 
obeseend Patient classified as obese 
at end of study 
period/censor date 
01/28/2019 
Generated by STATA to transform “bmiend” if BMI 
greater than or equal to 30 kg/m2 
Y=1 N=0, Dichotomous 
*Schizophrenia spectrum disorders include the following diagnoses from the DSM-5: schizophrenia, 
schizoaffective disorder, schizophreniform disorder, delusional disorder, psychotic disorders, and 
schizotypal personality disorder.36 
**Atypical or Second-Generation Antipsychotics is a class of antipsychotics commonly prescribed to 
patients with SMI.  It includes the following medications prescribed in the United State: aripiprazole, 
asenapine maleate, clozapine, iloperidone, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, 
and ziprasidone.37 
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Appendix 3: Extended Results 
 
Table A3-1: Results of Exploration of Data and Univariate Analysis 
Data  
set label 
 Description Type Missing? Range 
Check 
Distribution 
id Random study ID Continuous 0/119 2-992 - 
mos Number of complete 
months enrolled in 
Enhanced Model of 
Primary Care 
Continuous 0/119 18-35 Left-skewed   
mocat Total number of months 
enrolled by category 
0) 18-22 months 
1) 23 or more months 
Dichotomous 0/119 0-1 0: 62 
1: 57 
 
gend Sex: 0 Male, 1: female Dichotomous 0/119 0-1 0: 10,375 
1: 13018 
age Age in years Continuous 0/119 22-79 Normal 
distribution  
raceth Race/ethnicity:  1: White, 
non-Hispanic, 2: Black, 
non-Hispanic, 3: Hispanic/ 
Latino, 4: Other/ not 
recorded 
Categorical 0/119 1-4 1: 44 
2: 63 
3: 4 
4: 8 
dx Diagnosis of 
Schizophrenia spectrum 
disorder: 0: No 1: Yes 
Dichotomous 0/119 0-1 0: 59 
1: 60  
meds Active prescription for 
atypical antipsychotics 
0: No  
1: Yes  
Dichotomous  0/119 0-1 0: 37 
1: 82 
kgt0 Weight at enrollment (kg) Continuous 0/119 54.9- 
185.5 
Normal 
distribution 
kgt6 Weight at 6 mos (kg) Continuous 1/119 54.7- 181.4 
Normal 
distribution 
kgt12 
Weight at 12 mos (kg) 
Continuous 2/119 56- 
194.1 
Normal 
distribution  
kgt18 Weight at 18 mos (kg) Continuous 2/119 53.8- 201.4 
Normal 
distribution 
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kgt24 Weight at 24 mos (kg) Continuous 72/119 60.5-165.6 
Normal 
distribution 
kgt30 Weight at 30 mos (kg) Continuous 93/119 64.9-164.9 
Near Normal 
distribution 
kgend Weight at the end of study 
period/ censor date of 
01/28/2019 (kg) 
Continuous  0/119 53.8- 
201.4 
Near Normal 
distribution, 
slightly right 
skewed 
height Height (m) Continuous 0/119  1.45- 1.93 
Normal 
Distribution 
bmit0 
BMI at enrollment (kg/m2) 
Continuous 0/119 17.6- 
64.3 
Normal 
distribution 
bmit6 BMI at 6 mos (kg/m2) Continuous 1/119  17.3 – 66.7 
Normal 
distribution 
bmit12 BMI at 12 mos (kg/m2) Continuous 2/119 17.8- 70.5 
Normal 
distribution 
bmit18 BMI at 18 mos (kg/m2) Continuous 2/119  18- 75.6 
Normal 
distribution 
bmit24 BMI at 24 mos 
(kg/m2) 
Continuous 72/119 20.2- 
50.0 
Normal 
distribution 
bmit30 BMI at 30 mos 
(kg/m2) 
Continuous 93/119 20.0- 
51.7 
Normal 
distribution 
bmiend BMI at the end of study 
period/ censor date 
01/28/2019 
(kg/m2) 
Continuous 0/119 18-
75.6 
Nearly normal 
distribution, 
slightly right 
skewed 
Diab Diagnosis of type 2 
diabetes  Y=1 N=0 
Dichotomous 0/119 0-1 0: 78 
1: 41 
htn Diagnosis Hypertension 
Y=1 N=0 
Dichotomous 0/119 0-1 0: 46 
1: 73 
lipid Dyslipidemia Y=1 N=0 Dichotomous 0/119 0-1 0: 56 1: 63 
home Homelessness Y=1 N=0 Dichotomous 1/119 0-1 0: 107  1: 11 
employ Full time Employment?  Dichotomous  24/119 0-1  
0: 86  
1: 9 
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bmicatt0 BMI Classification at time 
of enrollment 
0= underweight 
1= normal/healthy weight 
2= overweight 
3= class I obesity 
4= class II obesity  
5= class III obesity  
Categorical 0/119 0-5 0: 2 
1: 20 
2: 26  
3: 25 
4: 17 
5: 29 
bmicatt6 BMI Classification after 6 
months 
0= underweight 
1= normal/healthy weight 
2= overweight 
3= class I obesity 
4= class II obesity  
5= class III obesity 
Categorical 1/119 0-5 0:2  
1: 16 
2: 25 
3: 26 
4: 21 
5: 28 
bmicatt12 BMI Classification after 12 
months 
0= underweight 
1= normal/healthy weight 
2= overweight 
3= class I obesity 
4= class II obesity  
5= class III obesity 
Categorical 2/119 0-5 0: 2 
1: 15  
2: 29 
3: 23 
4: 18  
5: 30 
bmicatt18 BMI Classification after 18 
months 
0= underweight 
1= normal/healthy weight 
2= overweight 
3= class I obesity 
4= class II obesity  
5= class III obesity 
Categorical 2/119  0-5 0: 1 
1: 16 
2: 28 
3: 26 
4: 17 
5L 29 
bmicatt24 BMI Classification after 24 
months 
0= underweight 
1= normal/healthy weight 
2= overweight 
3= class I obesity 
4= class II obesity  
5= class III obesity 
Categorical 72/119 0-5 0: 0 
1: 3 
2: 9 
3: 15 
4:10 
5:10 
bmicat30 BMI classification after 30 
months 
0= underweight 
1= normal/healthy weight 
2= overweight 
Categorical 93/119 0-5 0: 0 
1: 2 
2: 2 
3:10  
4: 7 
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3= class I obesity 
4= class II obesity  
5= class III obesity 
5: 5 
bmicatend BMI classification at end 
of study period/ censor 
date 01/28/2019 
0= underweight 
1= normal/healthy weight 
2= overweight 
3= class I obesity 
4= class II obesity  
5= class III obesity 
Categorical 0/119 0-5 0: 1 
1: 17 
2: 28 
3: 24  
4: 18  
5: 31 
obeset0 Patient classified as 
obese at time of 
enrollment 
0= No (BMI<30) 
1= Yes (BMI > 30) 
Dichotomous 0/119 0-1 0: 48 
1: 71 
obeset6 Patient classified as 
obese after 6 months 
0= No (BMI<30) 
1= Yes (BMI > 30) 
Dichotomous 1/119 0-1 0: 43 
1: 75 
obeset12 Patient classified as 
obese after 12 months 
0= No (BMI<30) 
1= Yes (BMI > 30) 
Dichotomous 2/119 0-1 0: 46 
1: 71 
obeset18 Patient classified as 
obese after 18 months 
0= No (BMI<30) 
1= Yes (BMI > 30) 
Dichotomous 2/119 0-1 0: 45 
1: 72 
obeset24 Patient classified as 
obese after 24 months 
0= No (BMI<30) 
1= Yes (BMI > 30) 
Dichotomous 72/119 0-1 0: 12 
1: 35 
obeset30 Patient classified as 
obese after 30 months 
0= No (BMI<30) 
1= Yes (BMI > 30) 
Dichotomous 93/119 0-1 0: 4 
1: 22 
obeseend Patient classified as 
obese at end of study 
period/censor date 
01/28/2019 
0= No (BMI<30) 
1= Yes (BMI > 30) 
Dichotomous 0/119 0-1 0: 46 
1: 73 
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Table A3-2: Characteristics of Obese Patients versus Non-Obese Patients at Baseline 
Enrollment and Censor Date 
 Obese Patients (BMI >30) Non-Obese Patients (BMI<30) 
Baseline 
n=71 
Censor Date 
n=73 
Baseline 
n=48 
Censor Date 
n=46 
  Percent (n) 
Gender     
    Male 36.6 (26) 35.6 (26) 56.3 (27) 58.7 (27) 
Female 63.4 (45) 64.4 (47) 43.8 (21) 41.3 (19) 
Race/Ethnicity     
    White, Non-
Hispanic 
36.6 (26) 35.6 (26) 37.5 (18) 39.1 (18) 
    Black, Non-
Hispanic 
52.1 (37) 53.4 (39) 54.2 (26) 52.2 (24) 
    Hispanic/Latino 4.2 (3) 4.1 (3) 2.1 (1) 2.2 (1) 
Other/Not 
Recorded 
7.0 (5) 6.9 (5) 6.3 (3) 6.5 (3) 
Diagnosis of 
Hypertension 
73.2 (52) 72.6 (53) 43.8 (21) 43.5 (20) 
Diagnosis of 
Diabetes 
42.3 (30) 38.4 (28) 22.9 (11) 28.3 (13) 
Diagnosis of 
Dyslipidemia 
62.0 (44) 56.2 (41) 39.6 (19) 47.8 (22) 
Homeless 11.3 (8) 11.0 (8) 6.4 (3) 6.7 (3) 
Full-time 
employment  
10.3 (6) 10.5 (6) 8.1 (3) 7.9 (3) 
Diagnosis of 
Schizophrenia 
Spectrum Disorder 
46.5 (33) 46.6 (34) 56.3 (27) 56.5 (26) 
Prescribed 
Atypical 
Antipsychotics 
66.2 (47) 63.0 (46) 72.9 (35) 78.3 (36) 
  Mean (SD) 
Age (years) 51.5 (11.1) 50.5 (12.1) 51.6 (13.6) 53.0 (12.0) 
Number of months 
enrolled  
25.3 (5.5) 25.5 (5.7) 23.0 (5.5) 22.6 (4.8) 
Baseline Weight 
(kg) 
111.2 (23.8) 110.6 (24.1) 76.3 (13.1) 75.6 (12.0) 
End Weight (kg) 112.1 (60.5) 113.9 (25.3) 79.1 (15.37) 74.8 (11.6) 
Baseline BMI 
(kg/m2) 
39.5 (7.8) 38.9 (8.2) 25.4 (3.2) 25.7 (3.7) 
End BMI (kg/m2) 39.8 (9.4) 40.2 (8.8) 26.6 (4.4) 25.3 (2.6) 
Height 1.67 (0.11) 1.68 (0.11) 1.72 (0.10) 1.72 (0.11) 
 
 
 
 
 
 
 51 
 
 
Table A3-3: Approach to Developing Final Etiologic Exposure-Outcome Model 
Illustration of the change-in-estimate approach taken to create final model as shown in Table 5. 
As a result of this approach, race/ethnicity, diagnosis of a schizophrenia spectrum disorder, and 
active prescription for atypical antipsychotics were removed from the model, because they were 
not found to be statistically significant confounders when assessing the magnitude of 
association between number of months enrolled at WakeBrook Primary Care and Obesity  
Model  OR  95% CI Difference 
from fully 
adjusted 
Drop 
or 
keep? 
  
Unadjusted  2.402344 1.120343- 
5.151331 
 
n/a    
Fully adjusted  2.725935 1.049578-
7.079719 
n/a n/a  10%= 0.275935 
Model 1: Drop 
age 
2.31989 0.9416641-
5.715298 
0.406045 Keep Reason: From table 5, 
mean age in exposed 
vs. non-exposed group 
is similar   
Model 2: Drop 
race and ethnicity  
2.652677 1.055202- 
6.66858 
0.073258 Drop Reason: From  table 5, 
it seems that race and 
ethnicity is reasonably 
distributed across 
exposure groups  
Model 3: Drop 
gender 
2.548552 1.044386- 
6.219081 
0.177383 Drop Reason: From table 5, 
mean age in exposed 
vs. non-exposed group 
is similar 
Model 4:  
Drop diagnosis of 
schizophrenia 
spectrum disorder 
2.47407 1.031774-
5.932524 
0.251865 Drop Reason: From table 5, 
diagnosis of 
schizophrenia 
spectrum disorder is 
reasonably distributed 
across exposure 
groups 
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Model 5: Drop 
active prescription 
for atypical 
antipsychotics 
2.489701 1.05597-
5.870063 
0.236234 Drop Reason: From table 5, 
active prescription for 
atypical antipsychotics 
is reasonably 
distributed across 
exposure groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
